Keywords
Diagnostic Techniques, Neurological ×
Show more Keywords
Table of contents
  1. 1. Clinical Trial
  2. 2. Routine Documentation
  3. 3. Registry/Cohort Study
  4. 4. Quality Assurance
  5. 5. Data Standard
  6. 6. Patient-Reported Outcome
  7. 7. Medical Specialty
Selected data models

You must log in to select data models for download or further analysis.

9 Search results.

Smart Device System Meta Data Definitions - PD NMS

- 9/3/20 - 7 forms, 1 itemgroup, 1 item, 2 languages
Itemgroup: PD NMS
Metadata definitions for the Smart Device System for Movement Disorders. Clinical Protocol and Registration Information available on: https://clinicaltrials.gov/ct2/show/NCT03638479 Principal Investigator: Julian Varghese Description for Assessment Steps for Neurologic Examination are available under: Varghese J, Niewöhner S, Soto-Rey I, et al. A Smart Device System to Identify New Phenotypical Characteristics in Movement Disorders. Front Neurol. 2019;10:48. doi:10.3389/fneur.2019.00048

Neurologic Examination

1 itemgroup, 6 items

Demography

2 itemgroups, 5 items

Medical History

1 itemgroup, 9 items

Family History

1 itemgroup, 2 items
2 other form meeting the search is available in the detailed view.

Baseline Visit (Day 1): EDSS evaluation BG00012 Monotherapy Safety and Efficacy Extension Study in Multiple Sclerosis (MS) (ENDORSE) NCT00835770

- 6/9/16 - 1 form, 4 itemgroups, 15 items, 1 language
Itemgroups: Subject Identification, EDSS Evaluation, Functional System Scores, EDSS, Additional and Results
The primary objective of this study is to evaluate the long-term safety profile of BG00012 (dimethyl fumarate). Secondary objectives of this study are to evaluate the long-term efficacy of BG00012 using clinical endpoints and disability progression, to evaluate further the long-term effects of BG00012 on multiple sclerosis (MS) brain lesions on magnetic resonance imaging (MRI) scans in participants who had MRI scans as part of Studies 109MS301 (NCT00420212) and 109MS302 (NCT00451451) and to evaluate the long-term effects of BG00012 on health economics assessments and the visual function test. NCT00835770 Part: Baseline Visit (Day 1)

Baseline: Evoked Potentials Multiple Sclerosis ALAIN01 NCT02419378 - Baseline: Evoked Potentials Multiple Sclerosis ALAIN01 NCT02419378

- 6/3/16 - 1 form, 1 itemgroup, 33 items, 1 language
Itemgroup: Evoked Potentials
Alemtuzumab in Autoimmune Inflammatory Neurodegeneration: Mechanisms of Action and Neuroprotective Potential (ALAIN01) https://clinicaltrials.gov/ct2/show/NCT02419378 Principal Investigator Prof. Dr. Dr. Sven Meuth, University Hospital Muenster, Germany Part: Baseline

Month 6: Evoked Potentials Multiple Sclerosis ALAIN01 NCT02419378

- 6/3/16 - 1 form, 1 itemgroup, 33 items, 1 language
Itemgroup: Evoked Potentials
Alemtuzumab in Autoimmune Inflammatory Neurodegeneration: Mechanisms of Action and Neuroprotective Potential (ALAIN01) https://clinicaltrials.gov/ct2/show/NCT02419378 Principal Investigator Prof. Dr. Dr. Sven Meuth, University Hospital Muenster, Germany Part: Month 6

Month 12: Evoked Potentials Multiple Sclerosis ALAIN01 NCT02419378

- 6/3/16 - 1 form, 1 itemgroup, 33 items, 1 language
Itemgroup: Evoked Potentials
Alemtuzumab in Autoimmune Inflammatory Neurodegeneration: Mechanisms of Action and Neuroprotective Potential (ALAIN01) https://clinicaltrials.gov/ct2/show/NCT02419378 Principal Investigator Prof. Dr. Dr. Sven Meuth, University Hospital Muenster, Germany Part: Month 12

Month 30: Evoked Potentials Multiple Sclerosis ALAIN01 NCT02419378

- 6/3/16 - 1 form, 1 itemgroup, 33 items, 1 language
Itemgroup: Evoked Potentials
Alemtuzumab in Autoimmune Inflammatory Neurodegeneration: Mechanisms of Action and Neuroprotective Potential (ALAIN01) https://clinicaltrials.gov/ct2/show/NCT02419378 Principal Investigator Prof. Dr. Dr. Sven Meuth, University Hospital Muenster, Germany Part: Month 30

Month 24: Evoked Potentials Multiple Sclerosis ALAIN01 NCT02419378

- 6/3/16 - 1 form, 1 itemgroup, 33 items, 1 language
Itemgroup: Evoked Potentials
Alemtuzumab in Autoimmune Inflammatory Neurodegeneration: Mechanisms of Action and Neuroprotective Potential (ALAIN01) https://clinicaltrials.gov/ct2/show/NCT02419378 Principal Investigator Prof. Dr. Dr. Sven Meuth, University Hospital Muenster, Germany Part: Month 24

Month 36: Evoked Potentials Multiple Sclerosis ALAIN01 NCT02419378

- 6/3/16 - 1 form, 1 itemgroup, 33 items, 1 language
Itemgroup: Evoked Potentials
Alemtuzumab in Autoimmune Inflammatory Neurodegeneration: Mechanisms of Action and Neuroprotective Potential (ALAIN01) https://clinicaltrials.gov/ct2/show/NCT02419378 Principal Investigator Prof. Dr. Dr. Sven Meuth, University Hospital Muenster, Germany Part: Month 36

Month 18: Evoked Potentials Multiple Sclerosis ALAIN01 NCT02419378

- 6/3/16 - 1 form, 1 itemgroup, 33 items, 1 language
Itemgroup: Evoked Potentials
Alemtuzumab in Autoimmune Inflammatory Neurodegeneration: Mechanisms of Action and Neuroprotective Potential (ALAIN01) https://clinicaltrials.gov/ct2/show/NCT02419378 Principal Investigator Prof. Dr. Dr. Sven Meuth, University Hospital Muenster, Germany Part: Month 18